Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05221021 · ClinicalTrials.gov registry record · Phase 4
Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
A Phase 4 study of Overactive Bladder Syndrome, sponsored by Walter Reed National Military Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT05221021 is a Phase 4 study of Overactive Bladder Syndrome that is actively recruiting participants, run by Walter Reed National Military Medical Center. The registered enrollment target is 152 participants, above the 108-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (41% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05221021, a Phase 4 study of Overactive Bladder Syndrome, is actively recruiting participants, sponsored by Walter Reed National Military Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.
Conditions Studied
Interventions
- DRUG Vaginal estrogen
- DRUG Mirabegron 50 MG [Myrbetriq]
Study Locations (1)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05221021
The ClinicalTrials.gov registry entry for NCT05221021 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (41% higher). The listed sponsor is Walter Reed National Military Medical Center, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Vaginal estrogen is the first listed.
NCT05221021 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05221021 about?
NCT05221021 is a clinical study titled "Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome". A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral M...
What is the current status of trial NCT05221021?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 152 participants. The study started on 2022-10-01. Estimated completion is 2027-01-30.
What conditions does trial NCT05221021 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome.
What interventions are being tested in trial NCT05221021?
The interventions under investigation include: Vaginal estrogen (DRUG), Mirabegron 50 MG [Myrbetriq] (DRUG).
Who is sponsoring clinical trial NCT05221021?
This trial is sponsored by Walter Reed National Military Medical Center, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05221021 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
COMPLETED · Phase 4
-
Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection
COMPLETED · Phase 4
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.